# Pizarra — PT-pseudo_48fb60dfd22f (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_48fb60dfd22f
Task: 1

Encounter: Urology - outpatient on 14 Feb 2025.
Referrer: Dr. T. Hendriks (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 68-year-old male
  - PSA: 24.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.986 ng/mL²
  - PSA velocity: 3.9 ng/mL/yr
  - Prior PSA: 16.9 ng/mL
  - Prostate volume: 24.35 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8596296 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Osteoarthritis
  - Problem list / PMHx: Hypertension, Osteoarthritis
  - Current medication: metoprolol, paracetamol PRN
  - Allergies: NKA
  - Additional notes: PSA 24 ng/mL. PI-RADS 5. PSAD 0.99. Prostate volume 24 mL. csPCa 0.86.

Vitals: weight 93 kg, height 189 cm, BMI 26.0, BP 130/73 mmHg, HR 68 bpm. Smoking: Non-smoker.

Chief complaint: Clinical reassessment sought after mpMRI acquisition and a PSA increase reaching 24.0 ng/mL.

History: A 68-year-old mechanical engineer initiated evaluation in September 2022 due to an elevated PSA reading. He is a non-smoker, and his prior biopsy bucket remains None. Long-standing hypertension is managed with metoprolol, while osteoarthritis discomfort is addressed with paracetamol taken only when necessary. He shares a home with his wife, and adult offspring stop by every week, with their son handling administrative correspondence. Moderate lower urinary tract symptoms produce an IPSS total of 12. A stable cardiology assessment occurred during autumn 2024, accompanied by routine thyroid and vascular checks. Joint stiffness limits his mobility, necessitating a walking frame for extended distances and a ground-floor consultation room. He explicitly denies unexplained weight loss, osseous pain, or nocturnal diaphoresis.

Physical examination: DRE — texture: symmetrically smooth; mobility: unrestricted; asymmetry: absent. The glandular surface presents without palpable nodules, aligning with a normal digital examination. General inspection notes a well-nourished individual in no acute distress, registering a BMI of 26.0. Hemodynamic parameters remain stable at 130/73 mmHg with a regular pulse of 68 bpm. Cardiovascular and respiratory auscultation yield unremarkable results.

Patient info: mechanical engineer; Married; Lives with partner; adult children visit weekly.
Next of kin: Adult son (primary contact).

Lifestyle: alcohol 18 units / week; exercise Running 3x/week, 5 km; IPSS score: 12/35 (moderate LUTS).

Recent other appointments: Endocrine — thyroid screening; Vascular surgery — varicose veins consult; Cardiology — annual review (stable, autumn 2024).
Admin: Mobility limitation (frame); ground-floor consult room preferred.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.75 +/- 0.10   (95% CI 0.54-0.95)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.10  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 0.81 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'firm': p +/- 1.96*dp does not cross the 0.5 threshold. Treat it as a strong prior that should only be overturned by explicit contradicting evidence. Measured accuracy in this tier on the labelled cohort: 1.0 over 28 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: biopsy-naive.

CRITERION VERDICT: BIOPSY.

The criterion: Biopsy when the mpMRI shows a PI-RADS 3 or higher lesion; defer when PI-RADS is 1-2.

In the labelled cohort this criterion matched the reading urologist in every one of the 24 biopsy-naive cases (20 of them PI-RADS 4-5 and biopsied, 4 of them PI-RADS 2 or unreadable and deferred).

Track record of this criterion on the labelled cohort: 24 of 24 cases matched the reading urologist. Departing from it needs a specific finding from a retrieved document, named explicitly - not a restatement of the panel numbers it already used.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the mpMRI show a PI-RADS 3 or higher lesion?
  - psa_trend (get_psa_trend) -> Is the PSA trend significant enough to warrant immediate action?
  - previous_notes (get_previous_notes) -> What is the prior management context and agreed-upon surveillance pathway?

This case hinges on the detailed findings from the mpMRI, the trajectory of the PSA, and the patient's prior management plan to determine the necessity of a biopsy.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only considered the structured panel, which includes PSA (24.0 ng/mL), PI-RADS (5), PSA density (0.986 ng/mL²), PSA velocity (3.9 ng/mL/yr), and prior biopsy status (None). It cannot weigh the clinical context such as the patient's history of hypertension, osteoarthritis, moderate LUTS (IPSS 12), or his specific lifestyle factors (alcohol intake, exercise).

WHY THE SUGGESTION COULD BE WRONG
The prior suggested biopsy with a high probability (0.75). This could be wrong because the guideline criterion is based on PI-RADS $\ge 3$, which is met, but the guideline also suggests omitting biopsy if PSA density is $< 0.10 \text{ ng/mL/cc}$ and no family history is present, which is not explicitly checked by the prior. The high aleatoric uncertainty ($H=0.81$) suggests the data itself is highly mixed, meaning the model struggles to distinguish this case, potentially due to conflicting signals like a high PI-RADS 5 and a very high PSA density.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the mpMRI show a PI-RADS 3 or higher lesion?
psa_trend - Is the PSA trend significant enough to warrant immediate action?
previous_notes - What is the prior management context and agreed-upon surveillance pathway?
laboratory panel - What is the full laboratory panel, specifically to confirm PSA density and check for other relevant markers?
laboratory panel - Specifically, check if PSA density is $< 0.10 \text{ ng/mL/cc}$ to apply risk stratification rules.

GUIDELINE ANCHOR
The guideline states that MRI-directed biopsy is the standard of care when MRI shows a suspicious lesion (PI-RADS $\ge 3$), but it also provides risk-adapted matrices linking PI-RADS scores to PSA density to guide the decision to perform a biopsy.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
{"case_id": "PT-pseudo_48fb60dfd22f", "radiology_report": "Tergooi MC Radiology | 10 February 2025 | mpMRI Prostate\n\nClinical indication: Evaluation of a 68-year-old gentleman with a progressive PSA trajectory (17.8 to 24.0 ng/mL) alongside moderate lower urinary tract symptoms. Study requested for anatomical localisation and staging.\n\nFINDINGS:\nGlandular volume measures 24.35 mL. Architectural symmetry is disrupted. A discrete focus occupies the right peripheral zone at the mid-gland posterior aspect, spanning 14 x 11 x 10 mm. T2-weighted sequences display profound hypointensity with obliteration of typical zonal boundaries. Diffusion mapping reveals severe signal restriction (b-value 1400) paired with depressed ADC values. Post-contrast dynamics demonstrate rapid, robust, and sustained uptake compared to surrounding tissue. Extracapsular spread and seminal vesicle involvement are absent. The prostatic capsule maintains continuity. Pelvic lymph nodes show no suspicious characteristics. Bladder and rectal mucosa appear normal.\n\nIMPRESSION:\nPI-RADS 5 lesion located in the right mid-peripheral zone.\nProstate volume 24.35 mL.\nPSAD 0.986 ng/mL/mL.\ncsPCa predicted probability 0.8596296."}
get_psa_trend
{"case_id": "PT-pseudo_48fb60dfd22f", "psa_trend": [{"date": "Sep 2022", "val": 11.8}, {"date": "Dec 2023", "val": 9.8}, {"date": "Feb 2025", "val": 24.0}]}
get_previous_notes
{"case_id": "PT-pseudo_48fb60dfd22f", "previous_notes": [{"date": "20 Feb 2024", "author": "Dr. T. Hendriks (GP)", "text": "Clinical review conducted during the annual health assessment. December 2023 testing recorded a PSA level of 16.9 ng/mL, reflecting a minor decline from the 17.8 ng/mL documented in September 2022. Persistent elevation alongside advanced age coincided with a multiparametric scan order and a specialist referral. Current regimen includes metoprolol for adequately controlled hypertension."}, {"date": "19 Jun 2024", "author": "Dr. T. Hendriks (GP)", "text": "Subsequent discussion addressed the pending specialist consultation. Imaging data returned indicating a highly suspicious focus. Referral documentation was advanced to the urology department. Lower urinary tract symptoms remain steady, yielding an IPSS score of 12. Autumn 2024 cardiology evaluation proved unremarkable."}]}
get_lab_results
{"case_id": "PT-pseudo_48fb60dfd22f", "laboratory_results": [{"name": "PSA", "val": "24.0 ng/mL", "date": "12 Jan 2025", "flag": "H"}, {"name": "Free PSA", "val": "2.48 ng/mL", "date": "12 Jan 2025", "flag": ""}, {"name": "%Free PSA", "val": "10%", "date": "12 Jan 2025", "flag": "L"}, {"name": "Haemoglobin", "val": "14.5 g/dL", "date": "12 Jan 2025", "flag": ""}, {"name": "WBC", "val": "7.6 x10^9/L", "date": "12 Jan 2025", "flag": ""}, {"name": "Platelets", "val": "232 x10^9/L", "date": "12 Jan 2025", "flag": ""}, {"name": "Creatinine", "val": "97 umol/L", "date": "12 Jan 2025", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "12 Jan 2025", "flag": ""}, {"name": "Testosterone", "val": "14.2 nmol/L", "date": "12 Jan 2025", "flag": ""}, {"name": "Alkaline phosphatase", "val": "87 U/L", "date": "12 Jan 2025", "flag": ""}, {"name": "LDH", "val": "145 U/L", "date": "12 Jan 2025", "flag": ""}, {"name": "HbA1c", "val": "6.3 %", "date": "12 Jan 2025", "flag": ""}]}

NOT RETRIEVED
The family history of prostate cancer was not retrieved, which could potentially influence risk stratification.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- mpMRI report: PI-RADS 5 lesion located in the right mid-peripheral zone.
- PSA trend: PSA increased from 16.9 ng/mL (Dec 2023) to 24.0 ng/mL (Feb 2025).
- previous_notes: Prior management involved a specialist referral based on imaging data indicating a highly suspicious focus.

AGAINST sampling this patient now:
- lab_results: %Free PSA is 10% (which is not explicitly $< 0.10 \text{ ng/mL/cc}$ as per LLM-1-GAP-ANALYST's suggestion, though the unit is %Free PSA).

WHERE THIS LEANS
The evidence strongly supports biopsy due to the PI-RADS 5 finding and the rising PSA velocity. This confirms the statistical prior and the guideline criterion.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes, laboratory_results. Open on the board so far: radiology_report, psa_trend, previous_notes, laboratory_results.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=yes, protocol=yes, evidence=yes.
Consensus: yes — unanimous among those who took a position.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes', 'laboratory_results']; still missing nothing.

The retrieved evidence, particularly the PI-RADS 5 finding from the MRI and the rising PSA trend, strongly supports the biopsy recommendation based on the expert protocol. The only missing piece is the family history, which was not retrieved.

The chair decides on the record as it stands.

## [9] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

The decision to biopsy is strongly supported by the convergence of evidence, as the PI-RADS 5 finding from the mpMRI is decisive, aligning with the guideline criterion. This was reinforced by the rising PSA trend, which increased from 16.9 ng/mL to 24.0 ng/mL. The statistical prior also suggested biopsy, and the retrieved evidence confirmed this direction, leading to a clear consensus.

Variables that carried weight: age=important, dre=noted, psa=decisive, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
